Subcutaneous biologics have revolutionized the administration of therapeutic proteins and antibodies, offering a convenient alternative to intravenous delivery. These biologics are injected into the subcutaneous tissue, allowing for self-administration and reducing the need for frequent hospital visits. This method is particularly beneficial for patients with chronic conditions such as rheumatoid arthritis, multiple sclerosis, and certain cancers. The subcutaneous route enhances patient compliance and comfort, as it is less invasive and time-consuming compared to intravenous infusions. Additionally, advancements in formulation technologies have enabled the delivery of high-dose and high-viscosity biologics through subcutaneous injections. Devices like autoinjectors and wearable pumps further facilitate this process, making it easier for patients to manage their treatments at home. Despite the challenges of ensuring drug stability and bioavailability, subcutaneous biologics have proven to be effective and well-tolerated. They also offer economic advantages by reducing healthcare costs associated with infusion therapies. Overall, the development of subcutaneous biologics represents a significant advancement in biotherapeutic delivery, improving the quality of life for patients and optimizing healthcare resources.